Abstract Objective To evaluate the efficacy and safety of iron protein succinylate(IPS) oral solution in preventing and treating anemia of prematurity(AOP). Methods Sixty premature infants less than 35 weeks of gestation were randomly divided into IPS(n=30) and polysaccharide iron complex(PIC) groups (n=30). Treatment began at two weeks after birth. The infants received IPS or PIC in addition to recombinant human erythropoietin. On days 14, 28, 42, and 60 after treatment, hemoglobin(Hb), red blood cell count (RBC), hematocrit(HCT), percentage of reticulocytes, serum iron, and serum ferritin were determined. Liver and renal functions were evaluated before and after treatment. Results There were significant differences in the changing trends of RBC and HCT between the two groups(P<0.05). In the IPS group, RBC and HCT gradually decreased after birth, but began to rise gradually on days 28 and 42 of treatment; in the PIC group, RBC and HCT kept decreasing from birth to day 60 of treatment. On day 60 of treatment, the IPS group had significantly higher levels of Hb, RBC, HCT, serum iron, and serum ferritin than the PIC group(P<0.05). No notable adverse events occurred in either group. Conclusions IPS oral solution has good efficacy and tolerability in preventing and treating AOP.
XING Yan,TONG Xiao-Mei. Clinical study of iron protein succinylate oral solution for preventing and treating anemia of prematurity[J]. CJCP, 2013, 15(12): 1059-1063.
XING Yan,TONG Xiao-Mei. Clinical study of iron protein succinylate oral solution for preventing and treating anemia of prematurity[J]. CJCP, 2013, 15(12): 1059-1063.
Steinmacher J, Pohlandt F, Bode H, Sander S, Kron M, Franz AR. Randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams: neurocognitive development at 5.3 years' corrected age[J].Pediatrics, 2007, 120(3): 538-546.
[2]
Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2012, 10: CD004865.
[3]
Mills RJ, Davies MW. Enteral iron supplementation in preterm and low birth weight infants[J]. Cochrane Database Syst Rev, 2012, 3: CD005095.
[4]
Sifakis S, Angelakis E, Papadopoulou E, Stratoudakis G, Fragouli Y, Koumantakis E. The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy[J]. Clin Exp Obstet Gynecol, 2005, 32(2): 117-122.
[5]
Careddu P, Scotti A. Controlled, double-blind, multicenter clinical trial of iron protein succinylate in the treatment of iron deficiency in children[J].Int J Clin Pharmacol Ther Toxicol, 1993, 31(4): 157-169.
Rosebraugh MR, Widness JA, Veng-Pedersen P. Multidose optimization simulation of erythropoietin treatment in preterm infants[J]. Pediatr Res, 2012, 71(4 Pt 1): 332-337.
[8]
Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes[J]. Cochrane Database Syst Rev, 2012, 8: CD003248.
[9]
Rao R, Georgieff MK. Iron therapy for preterm infants[J]. Clin Perinatol, 2009, 36(1): 27-42.
[10]
Afzal M, Qureshi SM, Lutafullah M, Iqbal M, Sultan M, Khan SA. Comparative study of efficacy, tolerability and compliance of oral iron preparations (iron edetae, iron polymatose complex) and intramuscular iron sorbitol in iron deficiency anaemia in children[J]. J Pak Med Assoc, 2009, 59(11): 764-768.
[11]
Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin treated premature infants[J]. Pediatrics, 2001, 107(1): 78-85.
[12]
Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1, 000 patients[J]. Int J Clin Pharmacol Ther Toxicol, 1993, 31(3): 103-123.
[13]
Liu TC, Lin SF, Chang CS, Yang WC, Chen TP. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study[J]. Int J Hematol, 2004, 80(5): 416-420.
[14]
Berglund S, Westrup B, Domellof M. Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weight infants[J]. Pediatrics, 2010, 126(4): e874-883.
[15]
Long H, Yi JM, Hu PL, Li ZB, Qiu WY, Wang F, et al. Benefits of iron supplementation for low birth weight infants: a systematic review[J]. BMC Pediatr, 2012, 12: 99.
[16]
Jesus Cancelo-Hidalgo M, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review[J]. Curr Med Res Opin, 2013, 29(4): 291-303.
